• Guerbet: Financial agenda for 2024

    Source: Nasdaq GlobeNewswire / 15 Jan 2024 11:00:00   America/Chicago

    Financial agenda for 2024

    Villepinte, 15 January 2024: Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2024.

    Publications calendar
    • 2023 ANNUAL REVENUE
    February 08, 2024, after trading
    • 2023 ANNUAL RESULTS
    March 20, 2024, after trading
    • 2024 1ST QUARTER REVENUE
    April 25, 2024, after trading
    • ANNUAL SHAREHOLDERS’ MEETING
    May 24, 2024
    • 2024 2ND QUARTER REVENUE
    July 25, 2024, after trading
    • 2024 FIRST HALF RESULTS
    September 25, 2024, after trading
    • 2024 3RD QUARTER REVENUE
    October 24, 2024, after trading

     

     

    About Guerbet

    At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a leader in medical imaging worldwide, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. A pioneer in contrast media for 95 years, with more than 2,600 employees worldwide, we continuously innovate and devote 10% of our sales to research and development in four centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022.

    Contacts :

    Guerbet     
    Jérôme Estampes, Chief Financial Officer + 33.1.45.91.50.00 / jerome.estampes@guerbet.com
    Claire Lauvernier, Group Communication Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.com

    Actifin        
    Marianne Py, Financial Communication + 33.1.80.48.25.31 / marianne.py@seitosei-actifin.com
    Jennifer Jullia, Media Relations +33.1.56.88.11.19 / jennifer.jullia@seitosei-actifin.com

    Attachment


Share on,